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Investigation of eNOS gene intron 4 A/B VNTR and intron 23
polymorphisms in patients with essential hypertension
İdris MEHMETOĞLU1, Gülsüm YILMAZ1, Sevil KURBAN1, Hasan ACAR2, M. Akif DÜZENLİ3

Aim: Nitric oxide (NO) plays a major role in the regulation of vascular tone. Production of NO can be influenced by
polymorphisms of the endothelial NO synthase (eNOS) gene, which may be associated with the pathogenesis of essential
hypertension (EHT). Therefore, eNOS gene intron 4 a/b variable number of tandem repeats (VNTR) and intron 23
polymorphisms were investigated in patients with EHT living in a central area of Turkey.
Materials and methods: The study was performed in 91 patients (34 M, 57 F) with EHT, aged 38-76 years, and 75 ageand sex-matched healthy controls (35 M, 40 F). eNOS gene polymorphisms were detected by polymerase chain reaction
method.
Results: There was no significant difference between the G-allele frequency of the G10-T polymorphism in intron 23 and
intron 4 a/b VNTR polymorphism of the eNOS gene in EHT patients and in the controls.
Conclusion: eNOS gene intron 4 a/b VNTR and intron 23 gene polymorphisms were not associated with EHT patients
living in a central area of Turkey. Further studies are needed to investigate whether these 2 polymorphisms of the eNOS
gene could represent useful genetic markers for indentifying individuals at risk of developing EHT.
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Esansiyel hipertansiyon hastalarında eNOS gen intron 4 a/b VNTR ve
intron 23 polimorfizimlerinin araştırılması
Amaç: Nitrik oksit (NO), vasküler tonusun düzenlenmesinde önemli bir rol oynar. NO’in üretimi esansiyel hipertansiyon
(EHT)’un patogenezi ile ilişkili olan endotelyal NO sentaz (eNOS) gen polimorfizimlerinden etkileniyor olabilir. Bundan
dolayı, çalışmamızda Türkiye’nin orta bölgesinde yaşayan EHT hastalarında eNOS gen intron 4 a/b değişken sayıdaki
ardışık tekrarlar (VNTR) ve intron 23 gen polimorfizimleri araştırıldı.
Yöntem ve gereç: Çalışma 38-76 yaşları arasındaki 91 EHT hastası (34 E, 57 K) ile uygun yaş ve cinsiyette 75 sağlıklı
kontrol (35 E, 40 K) vakası üzerinde gerçekleştirildi. eNOS gen polimorfizmleri polimeraz zincir reaksiyon metodu ile
belirlendi.
Bulgular: EHT hastaları ile kontrollerin eNOS gen intron 23 G10-T polimorfizminin G-allel sıklığı ile intron 4 a/b
VNTR polimorfizimleri arasında önemli bir fark bulunamadı.
Sonuç: eNOS geni intron 4 a/b VNTR ve intron 23 polimorfizimleri Türkiye’nin orta bölgesinde yaşayan EHT hastaları
ile ilişkili değildir. EHT gelişme riski olan kişilerin tanınmasında eNOS genindeki bu iki polimorfizmin faydalı birer
genetik markır olup olmayacağının anlaşılması için daha ileri çalışmalara ihtiyaç vardır.
Anahtar sözcükler: Esansiyel hipertansiyon, eNOS gen polimorfizmi, İntron 4 a/b VNTR, İntron 23
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Introduction
Hypertension is currently defined as a usual blood
pressure (BP) of 140/90 mm Hg or higher. In 90%95% of hypertensive patients, a single reversible cause
of the elevated BP cannot be identified: hence the
term essential or primary hypertension (EHT) (1).
Approximately 30% of the variance in BP was
reported to be attributable to genetic heritability (2,3).
Therefore, study of the candidate genes that may
contribute to the pathogenesis of HT may be a good
approach for understanding the etiology of EHT.
Nitric oxide (NO), derived from vascular
endothelium and various cells, is a simple and shortlived gas that plays a major role in the regulation of
vascular tone (4,5). It is synthesized from L-arginine
by the enzyme NO synthase (NOS) (6,7). It has key
functions in the relaxation of vascular smooth muscle,
inhibits adhesion of platelets and leukocytes, and
limits the oxidation of atherogenic low-density
lipoproteins (8).
The synthesis of NO by vascular endothelium is
responsible for the vasodilator tone that is essential
for the regulation of BP (9). Therefore, reduced NO
synthesis may be associated with the pathogenesis of
hypertension.
NO production can be influenced by
polymorphisms of the endothelial NOS (eNOS) gene.
Several investigations have been performed to show
the association between various eNOS gene
polymorphisms and coronary artery disease (CAD)
(6-8,10,11). However, studies on the association
between genetic polymorphisms of the eNOS gene
and EHT have been few and the findings are
conflicting (12,13).
The gene that encodes eNOS is located on
chromosome 7q35-36. It comprises 26 exons
spanning 21 kilobases, showing a 27 bp repeat
polymorphism in intron 4 of the gene intron 4 a/b
variable number of tandem repeats (VNTR)
(10,14,15).
The eNOS gene has 2 common alleles containing
4 repeats (a) and 5 repeats (b) which produce 2
homozygous (aa and bb) and 1 heterozygous (ab)
genotypes (15). In recent studies, the eNOS intron 4
a/b VNTR polymorphism has been found to be
associated with altered plasma NO levels and
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responsible for variations in the genetic control of
plasma nitrite and nitrate levels and enzyme
production (16-18).
In the present study, we investigated eNOS gene
intron 4 a/b VNTR and intron 23 polymorphisms in
patients with EHT and normotensive healthy controls
living in a central area (Konya) of Turkey.
Materials and methods
Subjects
Ninety-one patients with EHT (34 M and 57 F),
aged 38-76 (56.23 ± 9.0) years, and 75 healthy controls
(35 M, 40 F), aged 41-73 (55.43 ± 8.7) years, were
enrolled in the study. Subjects with BP equal to or
greater than 140 mmHg systolic and 90 mmHg
diastolic were defined as having HT. Informed
consent was obtained from all the subjects prior to
their enrollment in the study. Smoking, alcohol
consumption, HT, diabetes mellitus, and the family
history of all cases were recorded. HT patients with
any other risk factors were excluded from the study.
All diagnostic criteria were based on WHO
guidelines. The study was approved by the ethics
committee of the University of Selçuk’s Meram
Medical School.
Clinical and laboratory features of the subjects are
given in Table 1.
Laboratory analysis
Ten milliliters of venous blood samples were
obtained from all subjects into EDTA tubes. DNA
samples were separated immediately and stored at 80 °C until the time of analyses.
Determination
polymorphism

of

eNOS

4

a/b

VNTR

Genomic DNA from leukocytes was purified
according to the method of Miller et al. (19). The
eNOS gene intron 4, 27 bp VNTR polymorphism was
detected by polymerase chain reaction (PCR)
according to the method described by Wang et al. (16)
and Channon et al. (20). The template DNA (0.5 μg
per sample) was amplified using the following
primers: (forward) 5’-AGG CCC TAT GGT AGT
GCC TTT-3’ and 5’-TCT CTT AGT GCT GTG CTC
AC-3’ (reverse). These primers (10 pmol of each) were
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Table 1. Clinical and laboratory features of the controls and the hypertensive patients.
Features
Male/Female (n/n)
Age (years)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Smoking (n)
Total-C (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
TG (mmol/L)

Control (n = 75)

EHT (n = 91)

P

35/40
55.43 ± 8.7
<140
<90
27 (36%)
5.07 ± 0.242
3.07 ± 0.66
1.09 ± 0.33
2.21 ± 0.87

34/57
56.23 ± 9.0
≥140
≥90
58 (64%)
5.14 ± 1.017
3.13 ± 0.65
1.13 ± 0.19
2.24 ± 1.19

NS
NS
<0.01
<0.01
<0.001
NS
NS
NS
NS

(The values of lipids and ages are expressed as mean ± standard deviation.)
EHT: essential hypertension; BP: blood pressure; Total-C: total cholesterol; LDL-C: low-density lipoprotein choesterol; HDL-C: highdensity lipoprotein cholesterol; TG: trigycerides.

added to a mixture containing 0.2 μmol/L each of
dATP, dCTP, dGTP, and dTTP; 5 μL of 10× Cetus
buffer (pH 8.3); 5 μL of DMSO (100%); and 0.5 units
of Taq DNA Polymerase (Perkin Elmer Cetus), in a
final volume of 20 μL.
The PCR was initiated with a denaturation by first
heating the samples for 5 min at 94 °C. Thirty-five
cycles of denaturation for 1 min at 94 °C, annealing
for 1 min at 56 °C, primer extension for 2 min at 72
°C, and a last extension for 5 min at 72 °C were
applied for amplification. The PCR products of the
NO gene locus were examined by gel electrophoresis
(2% NuSieve agarose-agarose) at 150 V for 30 min
and visualized at room temperature under UV light
after ethidium bromide staining (Figure 1).
Determination of G10-T polymorphism in intron
23
For the G10-T polymorphism in intron 23 of the
eNOS gene, the primer pair for PCR was as follows:

forward, 5’-CCC CTG AGT CAT CTA AGT ATT C3’; reverse, 5’-AGC TCT GGC ACA GTC AAG-3’.
The resulting 676 bp amplification products were
incubated at 37 °C for 2 h with 10 U of the restriction
enzyme HindII (Bioron). The amplified DNAs were
then digested by HindII into fragments (577 and 99
bp). In the case of a G-to-T substitution at position 10
of intron 23 of the eNOS gene, an additional HindII
restriction site was produced and the amplified
fragments were digested into smaller fragments (374,
203, and 99 bp) (Figure 2). This polymorphism could
be determined in 90 patients and 61 controls.
Statistical analysis
The data was analyzed using the Statistical Package
for the Social Sciences (SPSS, Version 10.0).
Genotypic and allelic frequencies were determined
using the gene counting method. The chi-squared test
and Fisher’s exact test were performed for
independent relationships between variables.
Statistical significance was accepted at P < 0.05.
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Figure 1. Genotyping of the VNTR in intron 4 of eNOS gene.

Figure 2. Genotyping of the intron 23 of eNOS gene.
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In our study, we found no significant difference
between the EHT patients and controls in terms of the
allelic frequencies of the intron 4 VNTR or G10-T in
intron 23. Zintzaras et al. (22) have reported an
association between HT and eNOS 4b/a
polymorphism: under a recessive model, the allele b
provided evidence of protection, mainly when
analysis was confined to whites. However, they
reported no detectable influence of the G894T,
T786C, and G23T polymorphisms.

Results
The distribution of genotypes and allele
frequencies are compared between patients and
controls in Table 2. The genotype frequencies were in
agreement with Hardy-Weinberg equilibrium.
A comparison of genotypes and allelic frequencies
of the G10-T and intron 4 VNTR polymorphisms
between EHT patients and controls is shown in Table
2. There was no significant difference between the Gallele frequency of the G10-T polymorphism in intron
23 and intron 4 VNTR polymorphisms of the eNOS
gene in EHT patients and in controls.

Miyamoto et al. (23) found that the Glu298Asp
missense variant was significantly associated with
EHT, but found no such association between VNTR
in intron 4 (eNOS 4b/4a) and the disease. Benjafield
and Morris (24) have found no association of NOS3
markers (a biallelic VNTR in intron 4 and an exon 7
variant) in patients with EHT. Zhao et al. (13) found
no association between the T-786C, intron 4b/a, and
G894T polymorphisms of the eNOS gene in the
development of HT in a northern Han Chinese
population. Our findings about the eNOS gene intron
4 a/b VNTR were similar to the findings reported by
Miyamoto et al. (23), Zhao et al. (13), and Benjafield
and Morris (24).

eNOS 4a/b genotype frequencies in EHT patients
were 3.3%, 20.88%, and 75.82% for aa, ab, and bb,
respectively, and 1.3%, 21.33%, and 77.33% in the
control group for aa, ab, and bb, respectively.
Genotype frequencies were not significantly different
2
between groups (χ = 4.59, P = 0.10).
Moreover, we found no significant difference
between the allelic frequencies of the intron 4 VNTR
polymorphism in the EHT patients and in the
controls.

The difference between findings may be explained
in view of the genetic variability of populations.
Furthermore, it has been suggested that the difference
observed in the distribution of the eNOS intron 4a
allele might be due to the different sample sizes and
different selection criteria adopted for patients and
controls, in particular the clinical presentation, age,
race, geographic area, and environmental risk factors
(10).

Discussion
The incidence of HT may differ in each race or
ethnic group and the frequencies of eNOS gene
polymorphisms have been reported to vary among
ethnic groups (10-12,21). Therefore, findings about
the association between genetic polymorphisms of
eNOS genes and EHT are conflicting.

Table 2. Genotypic and allelic frequencies of eNOS gene intron 4a/b VNTR and intron 23 polymorphisms in controls and hypertensive
patients.
Genotypic frequency*
Polymorphisms

Intron 4 VNTR

G10-T
Polymorphism in
intron 23

Allelic frequency*

Groups
4a/4a

4a/4b

4b/4b

4a

4b

P

Control
EHT

1 (1.3%)
3 (3.3%)

16 (21.33%)
19 (20.88%)

58 (77.33%)
69 (75.82%)

0.12
0.14

0.88
0.86

NS
NS

Control
EHT

GG
61 (100%)
90 (100%)

GT
-

TT
-

G
1
1

T
0
0

P
NS
NS

*Genotypic and allelic frequencies were determined using the gene counting method.
EHT: essential hypertension; eNOS: endothelial nitric oxide synthase; NS: not significant; VNTR: variable number of tandem repeats.
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A previous study showed that eNOS 4a/b gene
polymorphism was not associated with HT in Turkish
patients (25). However, to our knowledge, no data are
available yet about the association between intron 23
polymorphism and EHT in the Turkish population.
Our results showed that there was no significant
association between the G10-T polymorphism in
intron 23 (G10-T) and EHT. However, Yoon et al.
(15), in their study on a Japanese population, found
that the genotypic frequency of G10-T polymorphism

in intron 23 of the controls was 87.5% GG and 12.5%
GT. This difference may be explained in view of the
genetic variability of the populations. However, the
influence of this difference on EHT needs to be
investigated further.
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